MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Prostamax Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Prostamax is a Khavinson peptide bioregulator extracted from young bovine prostate tissue (a polypeptide complex rather than a single defined sequence) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a prostate-targeted cytomedin. The mechanistic premise, paralleling other Khavinson preparations such as Prostatilen and Testagen, is that short peptides released by hydrolysis of the source extract enter prostate epithelial and stromal cells and modulate transcription of genes governing secretory function, microcirculation, and androgen receptor expression. Russian observational data report improvements in International Prostate Symptom Score, reductions in residual urine volume, and normalization of ejaculate parameters in chronic non-bacterial prostatitis. Researchers study it for benign prostatic hyperplasia, chronic prostatitis, and post-prostatectomy recovery. Context for the Khavinson cytomedin program is reviewed in PMID 21626751.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; use within 2 weeks.
Plasma half-life: Not characterized; Prostamax is a polypeptide complex rather than a single molecular entity, so pharmacokinetic parameters are not defined and effects are attributed to a mixture of short peptide fragments.
Typical cycle: 20 to 30 day oral capsule course at 1 to 2 capsules twice daily with food, repeated every 4 to 6 months. Often combined with Testagen or Endoluten in Russian urology protocols.
Regulatory status: Not approved by FDA, EMA, MHRA, or TGA. Marketed in Russia as a dietary peptide bioregulator; no Western randomized placebo-controlled trials support prostate indications.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Inject slowly and steadily; wait briefly before withdrawing.
Interactive Prostamax Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
2.5 Units (3 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase / Week | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 500 mcg (0.5 mg) | 5 units (0.05 mL) |
| Weeks 3–4 | 750 mcg (0.75 mg) | 7.5 units (0.075 mL) |
| Weeks 5–8 | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
| Weeks 9–12 (optional extension) | 1,000 mcg (1 mg) | 10 units (0.10 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Prostamax, 20 mg each):
- check8 weeks ≈ 2 vials (~40 mg total at ~0.7 mg/day average)
- check12 weeks ≈ 3 vials (~60 mg total)
- check16 weeks ≈ 4 vials (~80 mg total at ~1 mg/day maintenance)
Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- check8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
- check12 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- check16 weeks (4 vials): 8 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- check12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- check16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Mechanism of Action (MOA)
Prostamax consists of the linear tetrapeptide Lys-Glu-Asp-Pro. The Khavinson bioregulator hypothesis proposes that ultra-short peptides selectively penetrate the cells of their tissue of origin (in this case prostate), translocate to the nucleus, and form sequence-specific hydrogen bonds with short promoter motifs in DNA, thereby modulating transcription of genes whose function is relevant to that tissue's physiology [3]. For Prostamax, the proposed transcriptional targets include genes regulating prostatic epithelial differentiation, inflammatory cytokines (IL-1, IL-6, TNF-alpha), 5-alpha-reductase isoforms, androgen receptor signaling, and matrix remodeling enzymes. Cytogenetic studies have reported that Prostamax increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions in prostatic cells while reducing pericentromeric heterochromatin, consistent with chromatin decondensation and activation of previously silenced gene programs [4]. The peptide is hydrolyzed rapidly by gastrointestinal and plasma peptidases, so its biological effect must derive from a small fraction of intact peptide reaching target cells; this fraction has not been quantified in Western pharmacokinetic studies. The standard research route is oral capsules; parenteral cytogen formulations exist in Russian clinical practice but are not commercially standardized internationally. Typical research dosing is 200 to 400 mcg twice daily for 20 to 30 days, with cycles repeated every 4 to 6 months. Common research applications include chronic abacterial prostatitis (category IIIB), early-stage benign prostatic hyperplasia with lower urinary tract symptoms, recovery from prostate surgery (transurethral resection, simple prostatectomy), and general age-related decline in prostatic function. Downstream effects reported in animal models include reductions in prostatic inflammatory infiltrate, normalization of glandular architecture, and decreases in markers of oxidative stress in prostate tissue [5][6]. Reported clinical effects in Russian open-label studies include improvements in International Prostate Symptom Score (IPSS), increased maximum urinary flow rate (Qmax), decreased post-void residual volume, and improvements in patient-reported quality of life. Critical caveats include the absence of large randomized double-blind placebo-controlled trials, the lack of standardized formulations, and the variability in clinical outcomes across small uncontrolled studies. Prostamax should not be used as a substitute for established treatments for benign prostatic hyperplasia (alpha-blockers, 5-alpha-reductase inhibitors), chronic bacterial prostatitis (fluoroquinolones or trimethoprim-sulfamethoxazole), or prostate cancer (surgery, radiation, hormone therapy), and any urinary symptom warranting medical attention should first be evaluated by a urologist with appropriate imaging, PSA, and symptom-scale assessment. The Khavinson bioregulator framework positions Prostamax as a complementary tissue-modulation strategy intended to support long-term prostatic health rather than treat acute pathology, and most published Russian protocols emphasize cycling (20 to 30 days on, 4 to 6 months off) as an explicit feature rather than continuous dosing. Multi-peptide stacks combining Prostamax with Testagen (testicular peptide bioregulator) and Endoluten (pineal peptide bioregulator) are common in Russian clinical practice for age-related decline in male reproductive function, on the rationale that simultaneous tissue-specific modulation of the prostatic, testicular, and central neuroendocrine axes can compound the proposed gene-reactivation effects, although no formal pharmacokinetic or pharmacodynamic interaction studies among Khavinson peptides have been published in Western journals.
Clinical Trial Efficacy Highlights
- starIn rat models of chronic abacterial prostatitis induced by hormonal imbalance or chemical irritation, oral KEDP for 14 to 20 days reduced histological signs of inflammation, decreased stromal edema, and partially restored normal glandular architecture compared with vehicle controls [5].
- starKhavinson and colleagues reported that Prostamax-related peptides modulate gene expression in cultured prostate cells, increasing markers of differentiation and reducing inflammatory cytokine transcripts, consistent with the proposed epigenetic mechanism [4].
- starAn open-label Russian study of men with chronic abacterial prostatitis reported improvements in International Prostate Symptom Score, decreased pain on the NIH-Chronic Prostatitis Symptom Index, and improvements in quality-of-life domains after a 30-day course of Prostamax capsules [1].
- starCytogenetic studies have shown that Prostamax administration increases sister chromatid exchanges and decreases pericentromeric heterochromatin in prostate cells of aging animals, providing a mechanistic anchor for the proposed chromatin remodeling effect [4].
- starIn aged rats, multi-peptide Khavinson stacks including Prostamax-class compounds have been associated with reductions in markers of prostate aging (decreased connective tissue accumulation, reduced atypical hyperplasia, lower oxidative DNA damage markers) compared with age-matched controls [6].
- starRussian longitudinal cohort observations using multi-peptide bioregulator stacks (Prostamax plus Testagen plus Endoluten) reported reductions in functional age estimates and improvements in subjective wellness scores, but these observations lacked blinding and control comparators [7].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningAcross decades of Russian clinical use, Prostamax has been described as essentially free of serious adverse events at standard doses, with only rare mild gastrointestinal symptoms or transient headache reported.
- warningBecause the peptide is proposed to modulate prostatic gene expression, individuals with active prostate cancer or high-grade prostatic intraepithelial neoplasia should not use Prostamax outside of explicit research protocols.
- warningTheoretical concerns include alteration of PSA dynamics that could complicate cancer screening interpretation; men using Prostamax for any reason should disclose this to their urologist.
- warningNo formal drug-interaction studies have been published; concurrent use with alpha-blockers, 5-alpha-reductase inhibitors, or anticholinergics for BPH symptoms could produce additive or unpredictable effects.
- warningUse in women is not relevant given the tissue specificity; use in pediatric populations has not been studied and is not appropriate.
- warningMild dyspepsia and transient nausea have been described anecdotally with high-dose oral courses but are not consistently reported in published studies.
- warningNo teratogenicity, reproductive toxicity, or carcinogenicity studies meeting modern regulatory standards have been published; long-term safety relies on observational use rather than controlled data.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Prostamax dosage?expand_more
Standard Khavinson protocols use 1 to 2 oral capsules (approximately 200 mcg KEDP per capsule) twice daily for 20 to 30 days, with cycles repeated every 4 to 6 months. Parenteral cytogen formulations exist but lack standardized international dose guidance.
How is Prostamax used in research protocols?expand_more
Research applications focus on chronic abacterial prostatitis, mild to moderate benign prostatic hyperplasia, post-surgical recovery, and age-related prostatic decline. Outcome measures include IPSS, NIH-CPSI, uroflowmetry parameters, post-void residual volume, and quality-of-life domains.
Can Prostamax be combined with other peptides?expand_more
Within the Khavinson framework, Prostamax is commonly stacked with Testagen (testicular), Endoluten (pineal), and Cerluten (brain). Combinations with conventional BPH pharmacotherapy have not been formally evaluated and theoretically could produce additive symptom improvement.
What are the side effects of Prostamax?expand_more
Published Russian experience describes minimal adverse events at standard doses. Theoretical risks include altered PSA dynamics complicating cancer screening, unknown effects in active prostate malignancy, and absent toxicology data meeting Western regulatory standards.
Is Prostamax FDA approved?expand_more
No. Prostamax is not approved by the FDA, EMA, or other major Western regulators for any indication. It is not authorized as a drug or dietary supplement and is used only in research contexts and in Russian clinical practice under physician supervision.
Academic References & Study Citations
Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. View Scientific Paper →
Khavinson VK, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. View Scientific Paper →
Khavinson VK, Lin'kova NS, Pendina AA, et al. Effect of peptides on gene expression and protein synthesis in cell cultures. Bull Exp Biol Med. 2012;153(1):148-151. View Scientific Paper →
Pendina AA, Efimova OA, Fedorova ID, et al. DNA methylation patterns of metaphase chromosomes in cultured peripheral blood lymphocytes upon prolonged exposure to Khavinson peptides. Cell Tissue Biol. 2017;11(1):20-26. View Scientific Paper →
Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Peptides: prolongation of life of model organisms. Cells. 2020;9(7):1714. View Scientific Paper →
Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. View Scientific Paper →